Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2007) 14 P409

ECE2007 Poster Presentations (1) (659 abstracts)

Bone mineral density and bone markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid carcinoma

F. Mouton 1 , M. D’Herbomez 2 , C. Do Cao 1 , F. Tison-Muchery 2 , X. Marchandise 2 & J.-L. Wemeau 1


1Clinique d’Enocrinologie Marc Linquette, CHRU Lille, Lille, France; 2Service de Médecine Nuclaire, Hopital Roger Salengro, CHRU Lille, Lille, France.


Methods: In a prospective longitudinal study, 156 determinations of osteocalcine (OC) as a marker of bone formation, and of C-telopeptide of type-1 collagene (CTX and ICTP) as markers of bone resorption were performed in 103 patients {20 men (median age 50 years), 83 females (median age 56 years – 58% with age >50 years)} treated with suppressive levothyroxine therapy for DTC. Bone mineral density (BMD) of the hip was measured by dual X-ray absorptiometry (DXA) and lateral DXA pictures of the lumbar and thoracic vertebrae were performed (n=16 for 13 patients). The mean of follow-up was 9 years (range 0.5–36 years).

Results: All OC results, except three, were in the normal range. Thirsty one ICTP and 36 CTX levels were increased (together 13% of the evaluations). A positive significant correlation was found between the ICTP concentrations and the duration of the follow up (n=146, r=0.15, 0.02<P<0.05). BMD and resorption markers were concordant for 69% of the evaluations (7 with both normal, 4 with increased resorption markers and decreased BMD). For the discordant results, BMD were low in ostepenia for 4 patients with resorption markers in normal range, one isolated high ICTP concentration has been found.

Conclusion: 1) Only the resorption markers are increased in patients on long term LT4 therapy for DTC 2) prevalence of high CTX and ITP is the same for men and females >50 years (26%), lower (18%) for women <50 years 3) bone resorption markers could be used for screening patients at risk of osteopenia, when treated with suppressive levothyroxine therapy for DTC.

Article tools

My recent searches

No recent searches.